AR090884A1 - Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc - Google Patents
Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gccInfo
- Publication number
- AR090884A1 AR090884A1 ARP130101458A ARP130101458A AR090884A1 AR 090884 A1 AR090884 A1 AR 090884A1 AR P130101458 A ARP130101458 A AR P130101458A AR P130101458 A ARP130101458 A AR P130101458A AR 090884 A1 AR090884 A1 AR 090884A1
- Authority
- AR
- Argentina
- Prior art keywords
- gcc
- same
- antibody molecules
- directed therapy
- antibodies
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 101710095468 Cyclase Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639376P | 2012-04-27 | 2012-04-27 | |
| PCT/US2013/038542 WO2013163633A1 (en) | 2012-04-27 | 2013-04-27 | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090884A1 true AR090884A1 (es) | 2014-12-10 |
Family
ID=49477498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101458A AR090884A1 (es) | 2012-04-27 | 2013-04-29 | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc |
Country Status (41)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20196956B (en) | 2009-10-23 | 2019-03-25 | British Columbia Amgen | Anti-gcc antibody molecules and related compositions and methods |
| CA2928043A1 (en) * | 2013-10-21 | 2015-04-30 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
| US10351897B2 (en) | 2014-02-14 | 2019-07-16 | Bioventures, Llc | Acetaminophen adducts and methods of use thereof |
| AU2015358373B2 (en) | 2014-12-03 | 2021-05-27 | Arkansas Children's Research Institute | Anti-acetaminophen antibodies and acetaminophen protein adducts |
| US11090383B2 (en) | 2015-10-01 | 2021-08-17 | Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
| EP3551745A4 (en) * | 2016-12-12 | 2020-07-15 | Xcella Biosciences, Inc. | SCREENING METHODS AND SYSTEMS USING MICROCAPILLARY NETWORKS |
| KR102080887B1 (ko) * | 2017-11-07 | 2020-02-24 | 고려대학교 산학협력단 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
| US11568657B2 (en) | 2017-12-06 | 2023-01-31 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
| JP7197584B2 (ja) * | 2017-12-06 | 2022-12-27 | ベンタナ メディカル システムズ， インコーポレイテッド | デジタル病理学分析結果の格納および読み出し方法 |
| JP2021535180A (ja) * | 2018-09-05 | 2021-12-16 | ユニベルシテイト ファン アムステルダム | パーキンソン病の処置の為のｐｄｅ１１又はｐｄｅ２阻害剤の使用 |
| WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
| TW202210513A (zh) * | 2020-06-02 | 2022-03-16 | 日商帝人製藥股份有限公司 | 抗ｉｇｆ－１受體人源化抗體 |
| BR112023011658A2 (pt) * | 2020-12-17 | 2023-10-17 | Parasol Biotech Ltd | Anticorpo de domínio único anti-gucy2c (sdab), receptor de antígeno quimérico (car), ácido nucleico isolado, vetor, célula efetora imune manipulada, composição farmacêutica e método de tratamento de uma doença ou distúrbio em um sujeito |
| IL307367A (en) * | 2021-04-07 | 2023-11-01 | Lg Chemical Ltd | GUCY2C binding polypeptide and uses thereof |
| JP2025533779A (ja) * | 2022-09-28 | 2025-10-09 | レジェンド バイオテック アイルランド リミテッド | Ｇｃｃを標的とする抗体及びキメラ抗原受容体並びにそれらの使用方法 |
| KR20250099224A (ko) | 2022-11-01 | 2025-07-01 | 하이델베르크 파마 리서치 게엠베하 | 항-gucy2c 항체 및 이의 용도 |
| CN116535514B (zh) * | 2023-06-15 | 2024-02-02 | 上海斯丹赛生物技术有限公司 | 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用 |
| CN117069848B (zh) * | 2023-08-02 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人cd146兔单克隆抗体及其应用 |
| WO2025061149A1 (zh) * | 2023-09-21 | 2025-03-27 | 南京传奇生物科技有限公司 | 抗gcc抗体、嵌合抗原受体及其用途 |
| EP4566631A1 (en) | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
| ES2216004T3 (es) | 1993-10-26 | 2004-10-16 | Thomas Jefferson University | Composiciones que se unen especificamente a celulas cancerosas colorectales y procedimientos de uso de las mismas. |
| US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
| US7097839B1 (en) | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
| US6455251B1 (en) | 1994-09-13 | 2002-09-24 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| CA2254082C (en) | 1996-05-03 | 2012-09-11 | Thomas Jefferson University | Metastatic colorectal cancer vaccine |
| WO1997042506A1 (en) | 1996-05-03 | 1997-11-13 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| US6120995A (en) | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| US8092514B1 (en) | 1998-11-16 | 2012-01-10 | Boston Scientific Scimed, Inc. | Stretchable anti-buckling coiled-sheet stent |
| US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| JP2003535580A (ja) | 2000-03-27 | 2003-12-02 | トーマス ジェファーソン ユニバーシティ | 高特異性マーカー検出 |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| IL157041A0 (en) | 2001-01-26 | 2004-02-08 | Inhibitex Inc | Monoclonal antibodies to the clfa protein and method of use in treating and preventing infections |
| ES2539132T3 (es) | 2001-03-29 | 2015-06-26 | Synergy Pharmaceuticals, Inc. | Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis |
| JP4303475B2 (ja) | 2001-04-13 | 2009-07-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｖｌａ−１に対する抗体 |
| ES2289174T3 (es) | 2001-12-28 | 2008-02-01 | Amgen Fremont Inc. | Anticuerpos contra el antigeno muc-18. |
| US20040110933A1 (en) | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| EP1599165A4 (en) | 2003-02-10 | 2010-09-08 | Univ Jefferson | THE USE OF GCC LIGANDS |
| EP2357237A1 (en) | 2003-05-14 | 2011-08-17 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
| US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
| US8563682B2 (en) | 2004-06-25 | 2013-10-22 | Thomas Jefferson University | Guanylylcyclase C ligands |
| SI1838733T1 (sl) | 2004-12-21 | 2011-12-30 | Medimmune Ltd | Protitelesa usmerjena na angiopoietin-2 in njih uporaba |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| WO2009023457A1 (en) * | 2007-08-10 | 2009-02-19 | Centocor, Inc. | Immunoglobulin cleavage fragments as disease indicators and compositions for detecting and binding such |
| ES2517872T3 (es) | 2007-08-10 | 2014-11-04 | Regeneron Pharmaceuticals, Inc. | Anticuerpos humanos de alta afinidad para el factor de crecimiento nervioso humano |
| EP2220492B1 (en) * | 2007-11-30 | 2011-08-31 | Genentech, Inc. | Vegf polymorphisms and anti-angiogenesis therapy |
| CA2760050A1 (en) | 2008-05-13 | 2009-11-19 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
| EP2296685B1 (en) | 2008-06-04 | 2015-09-02 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| JP2011528375A (ja) | 2008-07-16 | 2011-11-17 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
| EP2370098A4 (en) | 2008-12-03 | 2013-07-17 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
| US9364477B2 (en) * | 2009-02-12 | 2016-06-14 | Cell Signaling Technology, Inc. | Mutant ROS expression in human cancer |
| CA2752668A1 (en) | 2009-02-25 | 2010-09-02 | Diagnocure Inc. | Method for detecting metastasis of gi cancer |
| WO2010104035A1 (ja) * | 2009-03-12 | 2010-09-16 | 学校法人近畿大学 | 非小細胞肺癌に対する化学療法の治療効果予測方法 |
| WO2010147684A1 (en) | 2009-06-15 | 2010-12-23 | Thomas Jefferson University | Compositions for and methods of activating guanylyl cyclase c |
| JP5955771B2 (ja) | 2009-10-22 | 2016-07-20 | トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 細胞ベースの抗癌組成物ならびに当該物の製造方法および使用方法 |
| GEP20196956B (en) * | 2009-10-23 | 2019-03-25 | British Columbia Amgen | Anti-gcc antibody molecules and related compositions and methods |
| WO2011150454A1 (en) * | 2010-06-01 | 2011-12-08 | Monash University | ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET |
| CA2806447A1 (en) * | 2010-08-13 | 2012-02-16 | F. Hoffmann-La Roche Ag | Neuropilin as a biomarker for bevacizumab combination therapies |
| WO2013016662A1 (en) | 2011-07-28 | 2013-01-31 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
| US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
| WO2014134311A1 (en) * | 2013-02-28 | 2014-09-04 | Millennium Pharmaceuticals, Inc. | Administration of an anti-gcc antibody-drug conjugate and a dna damaging agent in the treatment of cancer |
-
2013
- 2013-04-27 GE GEAP201313644A patent/GEP201706737B/en unknown
- 2013-04-27 PT PT137820619T patent/PT2841575T/pt unknown
- 2013-04-27 SA SA113340502A patent/SA113340502B1/ar unknown
- 2013-04-27 MY MYPI2014703176A patent/MY188442A/en unknown
- 2013-04-27 KR KR1020147032890A patent/KR102046435B1/ko not_active Expired - Fee Related
- 2013-04-27 CA CA2871614A patent/CA2871614C/en active Active
- 2013-04-27 ME MEP-2019-257A patent/ME03560B/me unknown
- 2013-04-27 NZ NZ701601A patent/NZ701601A/en not_active IP Right Cessation
- 2013-04-27 UA UAA201412715A patent/UA117910C2/uk unknown
- 2013-04-27 MA MA37569A patent/MA37569B1/fr unknown
- 2013-04-27 SG SG11201406855TA patent/SG11201406855TA/en unknown
- 2013-04-27 EA EA201491977A patent/EA034689B1/ru unknown
- 2013-04-27 ES ES13782061T patent/ES2749181T3/es active Active
- 2013-04-27 JP JP2015509208A patent/JP6472746B2/ja active Active
- 2013-04-27 PL PL13782061T patent/PL2841575T3/pl unknown
- 2013-04-27 LT LTEP13782061.9T patent/LT2841575T/lt unknown
- 2013-04-27 HR HRP20191690TT patent/HRP20191690T1/hr unknown
- 2013-04-27 HU HUE13782061A patent/HUE046404T2/hu unknown
- 2013-04-27 CN CN201380033309.4A patent/CN104395470B/zh active Active
- 2013-04-27 SI SI201331582T patent/SI2841575T1/sl unknown
- 2013-04-27 RS RSP20191239 patent/RS59370B1/sr unknown
- 2013-04-27 MX MX2014013081A patent/MX362020B/es active IP Right Grant
- 2013-04-27 US US13/872,080 patent/US9000129B2/en active Active
- 2013-04-27 DK DK13782061.9T patent/DK2841575T3/da active
- 2013-04-27 SM SM20190536T patent/SMT201900536T1/it unknown
- 2013-04-27 PE PE2014001908A patent/PE20142322A1/es active IP Right Grant
- 2013-04-27 WO PCT/US2013/038542 patent/WO2013163633A1/en not_active Ceased
- 2013-04-27 AU AU2013251312A patent/AU2013251312B2/en not_active Ceased
- 2013-04-27 EP EP13782061.9A patent/EP2841575B1/en active Active
- 2013-04-29 TW TW102115363A patent/TWI631137B/zh active
- 2013-04-29 AR ARP130101458A patent/AR090884A1/es active IP Right Grant
-
2014
- 2014-10-23 ZA ZA2014/07723A patent/ZA201407723B/en unknown
- 2014-10-23 IL IL235307A patent/IL235307B/en active IP Right Grant
- 2014-10-24 PH PH12014502399A patent/PH12014502399B1/en unknown
- 2014-10-24 TN TN2014000454A patent/TN2014000454A1/fr unknown
- 2014-10-24 DO DO2014000242A patent/DOP2014000242A/es unknown
- 2014-10-27 CL CL2014002911A patent/CL2014002911A1/es unknown
- 2014-10-27 CR CR20140497A patent/CR20140497A/es unknown
- 2014-11-25 EC ECIEPI201428523A patent/ECSP14028523A/es unknown
- 2014-11-26 CO CO14260074A patent/CO7280144A2/es unknown
-
2015
- 2015-02-27 US US14/634,438 patent/US9273146B1/en active Active
-
2016
- 2016-01-19 US US15/000,950 patent/US20160130344A1/en not_active Abandoned
-
2017
- 2017-04-26 JP JP2017087084A patent/JP6517267B2/ja active Active
-
2019
- 2019-09-24 CY CY20191101005T patent/CY1122557T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090884A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
| PH12021550083A1 (en) | Human anti-tau antibodies | |
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| CY1122907T1 (el) | Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1 | |
| CY1123515T1 (el) | Μεθοδοι αγωγης μιας ταυπαθειας | |
| MX366965B (es) | Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina. | |
| AR091649A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos | |
| AR088514A1 (es) | Inmunoligantes biespecificos dirigidos contra tnf | |
| AR088512A1 (es) | Anticuerpos dirigidos contra el tnf | |
| CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
| BR112015012933A2 (pt) | proteínas de ligação ao antígeno bcma | |
| UY32971A (es) | Proteínas de unión al antígeno de la il-23 humana | |
| BR112013021134A8 (pt) | Anticorpo isolado que se liga especificamente a ptk7 humano, seu uso, composição farmacêutica que o compreende, e ácido nucleico | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| CO7151488A2 (es) | Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos | |
| AR090923A1 (es) | Anticuerpos anti-il-23 | |
| AR063840A1 (es) | Anticuerpos humanos monoclonales para btla y metodos de uso | |
| MX2010000537A (es) | Anticuerpos monoclonales contra glipicano-3. | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| MX345092B (es) | Anticuerpos anti-tau humanos,. | |
| BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
| BR112014003999A2 (pt) | anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp | |
| DOP2013000218A (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
| BR112014032916A2 (pt) | anticorpos anti-fármacos e usos destes para o monitoramento de fármaco | |
| UY33274A (es) | Proteínas de unión a basigina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |